Literature DB >> 2425315

Epidural hydromorphone for postcesarean analgesia.

D H Chestnut, W W Choi, T J Isbell.   

Abstract

The efficacy of epidurally administered hydromorphone for postcesarean analgesia was evaluated in a prospective, randomized, double-blind study. Patients in group H (N = 26) received 1.0 mg of hydromorphone in preservative-free saline (total volume = 10 mL), administered epidurally. Patients in group B (N = 26) received 10 mL of 0.25% bupivacaine, administered epidurally. Both groups subsequently received intramuscular injections of hydromorphone as needed. There were significant differences between the two groups in pain score, patient assessment of analgesia quality, time to first analgesic intervention, and total dosage of hydromorphone during the first 24 hours. Nausea/vomiting and pruritus occurred more frequently in group H. No patient had a respiratory rate less than or equal to 10. There were no statistically significant differences between groups in mean times to first ambulation, first void, first passage of flatus, or hospital discharge.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425315

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

Review 1.  Epidural local anaesthetics versus opioid-based analgesic regimens for postoperative gastrointestinal paralysis, vomiting and pain after abdominal surgery.

Authors:  Joanne Guay; Mina Nishimori; Sandra Kopp
Journal:  Cochrane Database Syst Rev       Date:  2016-07-16

2.  Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure.

Authors:  Terhi Puhto; Merja Kokki; Henriikka Hakomäki; Michael Spalding; Teemu Gunnar; Seppo Alahuhta; Merja Vakkala
Journal:  Eur J Clin Pharmacol       Date:  2020-05-03       Impact factor: 2.953

3.  Postoperative Analgesic Effects of Different Doses of Epidural Hydromorphone Coadministered with Ropivacaine after Cesarean Section: A Randomized Controlled Trial.

Authors:  Meijuan Yang; Luyang Wang; Hong Chen; Yuwen Tang; Xinzhong Chen
Journal:  Pain Res Manag       Date:  2019-03-03       Impact factor: 3.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.